Introduction
Atenolol (Tenormin, I.C.I. 66082) is a new cardioselective adrenoceptor beta-blocking agent of similar potency to propranolol in animals that lacks partial agonist activity and membrane stabilizing effects. We report here the findings of a study that was designed to compare the efficacy of atenolol, bendrofluazide, and combined treatment with atenolol and bendrofluazide in a carefully selected group of hypertensive outpatients.
Patients and methods

SELECTION OF PATIENTS
Patients, aged 21-65 years, referred for investigation of raised blood pressure were assessed in hospital after at least 14 Patients were excluded if there was a history of recent myocardial infarction, evidence of cardiac failure, heart block, or gross ischaemia, grade III or IV retinopathy (Keith-Wagener), diabetes mellitus, gout, impaired liver function, creatinine clearance less than 60 ml/min, or if they were on any other drug treatment.
During a 36-48 hour hospital admission routine haematological, bacteriological, and biochemical investigations and chest x-ray examination, intravenous pyelography, and electrocardiography were performed. Lying and standing blood pressures were recorded every four hours. The observers in the trial (D.B.G. or J.C.P.) also measured the blood pressures with Hawksley random-zero sphygmomanometers on two separate occasions on the evening of admission (20.00-21.00 hours) and after a 10-hour overnight rest (08.00-09.00 hours). On both these occasions the number of 12 in steps required to produce an increment of standing pulse of 30 beats/minute was determined using electrocardiographic control. Patients were invited to participate in the trial if the morning lying diastolic pressures were over 90 mm Hg and under 105 mm Hg, and all other outpatient and ward blood pressures confirmed persistent readings above 90 mm Hg. The nature of the trial was explained and all suitable patients gave their consent.
Before discharge from hospital the patients were familiarized with a standard questionnaire about general health and the occurrence and severity of several symptoms. The methods of access to the doctors conducting the study were outlined.
CONDUCT OF TRIAL
After discharge from hospital the patients were seen at the hypertension clinic within two weeks. The protocol excluded patients from further participation in the trial if the lying diastolic blood pressure fell below 90 mm Hg after a four-week outpatient run-in period on a matching placebo. After the run-in period a double-blind cross-over method was used to assess the effects on lying, standing, and postexercise blood pressure of the following four treatments, each provided by two identical-looking tablets and given twice daily:
(a) Atenolol 100 mg; (b) atenolol 200 mg; (c) bendrofluazide 2-5 mg; (d) atenolol 100 mg and bendrofluazide 2-5 mg; each treatment was given for four weeks and each patient received the four treatments. Open pilot work had shown that no further hypotensive effect of atenolol occurred after two weeks, but we chose a four-week period to confirm this with a double-blind technique. The order of administration was determined by a random code which ensured that each of the 24 possible permutations of four treatments was given to one of the 24 patients. Thus each treatment period followed or preceded any other treatment period on six occasions. Two-week supplies of drugs were supplied to each patient in prepacked and paired containers.
The patients were seen every two weeks and the blood pressure of each patient was recorded using Hawksley random-zero sphygmomanometers under standard conditions at the same time of day by the same observer (D.B.G. or J.C.P.), except on a few occasions when a deputy substituted (J.W.). The mean of two or three blood pressure readings (same arm) after three to five minutes lying and two to three minutes standing was recorded. A single reading was taken after performance of the predetermined exercise load specified for each patient. The diastolic end point was taken as the phase-4 muffle. Between-observer comparisons of the blood pressure readings were made at intervals throughout the trial.
The observer not recording the blood pressure completed the questionnaire on symptoms in another room. Separate forms were ( The double-blind cross-over within-patient design was chosen to allow each patient to act as his own control for the different drugs and doses. All 24 patients completed the five-month study, in which each of the treatments followed or preceded any other on six occasions. An elaboration of the balanced design to include "washout" periods between treatment periods would have been of additional value in attempting to reduce further any effects due to the order of administration of the treatments, though a further three months (seven visits) without treatment would have been required for each of the 24 hypertensive patients.
The dose of 200 mg/day of atenolol was chosen on the basis that near maximal blockade of cardiac beta-receptors, as measured by inhibition of exercise tachycardia, should occur.3 A higher dose, 400 mg/day, was also included in the study as the relationship between cardiac beta-blockade and the antihypertensive effect of beta-blocking agents is not clear. Some investigators, using agents such as propranolol, have recommended doses greater than those needed for maximal betablockade.45 It is of interest that doubling the dose of atenolol, a cardioselective agent without membrane-stabilizing effect or partial agonist activity, resulted in no further reduction in blood pressure.
The dose of bendrofluazide selected (5 mg/day) and the treatment period on combined beta-blocker and diuretic reflects current clinical practice. Some comparisons may also be attempted with our findings in a similar study of practolol and bendrofluazide.6 Identical selection criteria and blood pressure measurement methods were used. Combined treatment with atenolol and bendrofluazide seems to reduce lying blood pressure (-33/22 mm Hg from 170/107 mm Hg) more than combined treatment with practolol and bendrofluazide (-28/13 mm Hg from 167/104 mm Hg).
There was no evidence of any influence of atenolol on the haematological or biochemical indices, with the exception of blood urea. Sporadic rises above normal were noted during active treatment periods, and during administration of the most effective treatment, atenolol 200 mg and bendrofluazide 5 mg, the mean blood urea levels just exceeded the upper limit of normal. Since effective treatment of hypertension with most drugs, including propranolol, may be associated with a slight reduction in renal function we do not think that this finding has any sinister significance.
The formulae of atenolol (4-(2-hydroxy-3-isopropylaminopropoxy) phenylacetamide) and practolol (4-(2-hydroxy-3-isopropylaminopropoxy) acetanilide) look similar but differ chemically in the side chain and in their theoretical metabolites. It is thought that the acetanilide side chain may cause the adverse effects on skin, eyes, or peritoneum that have been reported in association with practolol treatment. Similar effects have not been seen in treatment with atenolol, but long-term observation is required with this drug, as it is for all betablockers, until the aetiology of the practolol-induced reaction has been elucidated. Further studies on this new cardioselective beta-blocker are awaited with interest.
